

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

{BOX}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Milprazon 2.5 mg/25 mg tablets

For memory stickers:
milbemycin oxime/praziquantel

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains: milbemycin oxime 2.5 mg and praziquantel 25.0 mg.

3. PACKAGE SIZE

2 tablets
4 tablets
48 tablets

4. TARGET SPECIES

Small dogs and puppies (weighing at least 0.5 kg).



5. INDICATIONS

For products not subject to veterinary prescription:

Flavoured broad spectrum anthelmintic
Treatment of mixed infections by adult tapeworms and roundworms

6. ROUTES OF ADMINISTRATION

Oral use.

For products not subject to veterinary prescription:

Dosage:

Body weight	Tablets
0.5 – 1 kg	1/2 tablet
> 1 – 5 kg	1 tablet
> 5 – 10 kg	2 tablets

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Shelf life for halved tablets after first opening the immediate packaging: 6 months.

9. SPECIAL STORAGE PRECAUTIONS

Store in the original package in order to protect from moisture.
Halved tablets should be stored below 25°C in the original blister and be used for the next administration.
Keep the blister in the outer carton.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA

14. MARKETING AUTHORISATION NUMBERS

Vm 01656/3075

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

{BLISTER}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Milprazon



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

2.5 mg/25 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

KRKA

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Milprazon 2.5 mg/25 mg tablets for small dogs and puppies weighing at least 0.5 kg
Milprazon 12.5 mg/125 mg tablets for dogs weighing at least 5 kg

2. Composition

Each tablet contains:

	Tablets for small dogs and puppies	Tablets for dogs
Active substances:		
Milbemycin oxime	2.5 mg	12.5 mg
Praziquantel	25 mg	125 mg

Tablets for small dogs and puppies: Yellowish-white with brown spots, oval, biconvex tablets scored on one side.

The tablets can be divided into halves.

Tablets for dogs: Yellowish-white with brown spots, round, slightly biconvex tablets.

3. Target species

Small dogs and puppies (weighing at least 0.5 kg).

Dogs (weighing at least 5 kg).

4. Indications for use

Treatment of mixed infections by adult tapeworms and roundworms of the following species:

- Tapeworms:

Dipylidium caninum

Taenia spp.

Echinococcus spp.

Mesocestoides spp.

- Roundworms:

Ancylostoma caninum

Toxocara canis

Toxascaris leonina

Trichuris vulpis

Crenosoma vulpis (Reduction of the level of infection).

Angiostrongylus vasorum (Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under section “Dosage for each species, routes and method of administration”).

Thelazia callipaeda (see specific treatment schedule under section “Dosage for each species, routes and method of administration”).

The veterinary medicinal product can also be used in the prevention of heartworm disease (*Dirofilaria immitis*), if concomitant treatment against tapeworms is indicated.

5. Contraindications

Do not use “**tablets for small dogs and puppies**” in animals of less than 2 weeks of age and/or weighing less than 0.5 kg.

Do not use “**tablets for dogs**” in animals weighing less than 5 kg.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

See also section “Special warnings”.

6. Special warnings

Special warnings:

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

It is recommended to treat all the animals in the same household concomitantly.

In order to develop an effective worm control programme local epidemiological information and the risk of exposure of the dog should be taken into account, and it is recommended to seek professional advice.

When *D. caninum* infection is present, concomitant treatment against intermediate hosts, such as fleas and lice, should be considered to prevent re-infection.

Special precautions for safe use in the target species:

Studies with milbemycin oxime indicate that the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed.

The tolerance of the veterinary medicinal product in young puppies from these breeds has not been investigated.

Clinical signs in Collies are similar to those seen in the general dog population when overdosed.

Treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the veterinary medicinal product. The use in dogs suffering from microfilaremia is thus not recommended.

In heartworm risk-areas, or in the case it is known that a dog has been travelling to and from heartworm risk regions, before using the veterinary medicinal product, a veterinary consultation is advised to exclude the presence of any concurrent infestation of *Dirofilaria immitis*. In the case of a positive diagnosis, adulticidal therapy is indicated before administering the veterinary medicinal product.

No studies have been performed with severely debilitated dogs or individuals with seriously compromised kidney or liver function. The veterinary medicinal product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.

In dogs less than 4 weeks old, tapeworm infection is unusual. Treatment of animals less than 4 weeks old with a combination veterinary medicinal product may therefore not be necessary.

As the tablets are flavoured, they should be stored in a safe place out of the reach of animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Other precautions:

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (WOAH), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

Pregnancy and lactation:

Can be used during pregnancy and lactation.

Fertility:

Can be used in breeding animals.

Interaction with other medicinal products and other forms of interaction:

No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the combination of milbemycin oxime and praziquantel at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of the veterinary medicinal product and other macrocyclic lactones. Also, no such studies have been performed with reproducing animals.

Overdose:

No data available.

7. Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction; Systemic disorders (e.g. lethargy); Neurological disorders (e.g. muscle tremors and ataxia (incoordination)); Digestive tract disorders (e.g. emesis (vomiting), diarrhoea, anorexia (loss of appetite) and drooling).
--	--

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Oral use.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally.

Depending on the bodyweight of the dog, the practical dosing is as follows:

Body weight	Tablets for small dogs and puppies	Tablets for dogs
0.5 – 1 kg	1/2 tablet	
more than 1 – 5 kg	1 tablet	
more than 5 – 10 kg	2 tablets	
5 – 25 kg		1 tablet
more than 25 – 50 kg		2 tablets
more than 50 – 75 kg		3 tablets

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, the veterinary medicinal product can replace the monovalent veterinary medicinal product for the prevention of heartworm disease.

For treatment of *Angiostrongylus vasorum* infections, milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against tapeworms is indicated, to treat once with the veterinary medicinal product and continue with the monovalent veterinary medicinal product containing milbemycin oxime alone, for the remaining three weekly treatments.

In endemic areas administration of the veterinary medicinal product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against tapeworms is indicated.

For the treatment of *Thelazia callipaeda*, milbemycin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against tapeworms is indicated, the veterinary medicinal product can replace the monovalent veterinary medicinal product containing milbemycin oxime alone.

9. Advice on correct administration

The veterinary medicinal product should be administered with or after some food.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store in the original package in order to protect from moisture. This veterinary medicinal product does not require any special temperature storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the blister and carton after Exp. The expiry date refers to the last day of that month.

Shelf life for halved tablets for small dogs and puppies after first opening the immediate packaging: 6 months.

Halved tablets should be stored below 25°C in the original blister and be used for the next administration.

Keep the blister in the outer carton.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

This veterinary medicinal product should not enter water courses as milbemycin oxime may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription (BG, CY, GR, HU, PL, CZ, DE, EE, ES, HR, IE, IT, LV, PT, RO, SI, SK, UK (NI)).

Veterinary medicinal product not subject to prescription (BE, NL).

Veterinary medicinal product subject to prescription except for some pack sizes (FR, SE).

14. Marketing authorisation numbers and pack sizes

Vm 01656/3075

Box with 1 blister of 2 tablets.

Box with 1 blister of 4 tablets.
Box with 12 blisters, each blister contains 4 tablets.
Not all pack sizes may be marketed.

15.PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Manufacturer responsible for batch release:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

KRKA-FARMA d.o.o., V. Holjevca 20/E, Jastrebarsko, 10450, Croatia

TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information